Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: post hoc analyses from paloma-2 and paloma-3

HIGHLIGHTS

• who: Hope S. Rugo from the University of California, San Francisco, Helen Diller Family Comprehensive Center, Department of Medicine (Hematology/Oncology), th Street, rd Floor, Box, San Francisco, CA, USA have published the research: Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptoru2012positive/human epidermal growth factor receptor 2u2012negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3, in the Journal: (JOURNAL) of May/31,/2017
• how: Regardless of treatment patients with poor prognosis (DFI u2264 12 months ET resisu00ad tance visceral disease and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.